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LETTER TO THE EDITORRe: Alemtuzumab-Induced
Resolution of Pulmonary
Noninfectious Complications
in a Patient with Chronic
Graft-versus-Host Disease
Despite recent significant advances in the field of
hematopoietic stem cell transplantation (HSCT),
there has been little change in the incidence, morbid-
ity, and mortality of chronic graft-versus-host disease
(cGVHD). Pulmonary complications occur in approx-
imately 25% of HSCT recipients and account for in-
creased mortality and morbidity [1]. Approximately
40% of these cases are noninfectious, most of them re-
lated to GVHD [1]. Several months ago, we reported
a 19-year-old patient with extensive cutaneous
GVHD affecting 100% of her body surface that had
been treated unsuccessfully for 9 months with steroids,
cyclosporine-A, sirolimus, tacrolimus, mycophenolate
mofetil, infliximab, and rituximab. Treatment was
started with alemtuzumab, 10mg/day s.c. for 6 consec-
utive days every 4 weeks. Her skin condition resolved,
with all cutaneous ulcers disappearing [2]. Subse-
quently, the dosage was decreased to 10 mg every 10
days. The patient remained well for the next 20
months. But 6 weeks after alemtuzumab treatmentFigure 1. The initial chest radiograph showed diffuse reticulonodular areas of
obtained 10 days later showing disease progression, with diffuse patchy consolid
adenopathy can be seen. B, Complete resolution of all lung lesions with no re
1434was interrupted because of a dental procedure, she de-
veloped exertional dyspnea, and then was admitted to
the hospital with severe hypoxemia. A comprehensive
laboratory workup failed to reveal infectious complica-
tions, despite the radiographic findings in both lungs
(Figure 1A). The patient refused a pulmonary biopsy.
She was treated with i.v. steroids, wide-spectrum anti-
biotics, and antiviral agents without improvement.
When an endotracheal tube was about to be inserted,
she was restarted on alemtuzumab, 10 mg/day s.c.
Her pulmonary condition improved significantly,
and pulmonary infiltrates resolved (Figure 1B). She
was able to return home 7 days later with a Karnofsky
score of 80%. Her respiratory condition stabilized
over the next 2 months, with an alemtuzumab dosage
of 10 mg every 10 days.
There have been reports on the use of alemtuzu-
mab in treating acute GVHD (aGVHD) [3], but very
few reports on its use in treating chronic GVHD [2].
Although alemtuzumab has been used to successfully
treat bronchiolitis obliterans syndrome after human
lung transplantation [4], to the best of our knowledge,
there are no reports of its use in treating late noninfec-
tious pulmonary complications after HSCT. Despite
the fact that we were unable to prove that GVHD
was responsible for the lung injury in this patient and
could not define the type of pulmonary damage that
she sustained, the alemtuzumab treatment clearly im-
proved this patient’s pulmonary condition. Studiesincreased density in both lungs as in viral pneumonia. A, Chest radiograph
ation and large nonnecrotic nodules in both lungs; no hilar or mediastinal
strictive pattern 20 days after starting alemtuzumab treatment.
Biol Blood Marrow Transplant 14:1434-1435, 2008 1435Letter to the Editorare needed to assess the efficacy of alemtuzumab in
treating human GVHD.
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